非小细胞肺癌发生胸膜侵犯的研究进展
Research Progress of Pleural Invasion in Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2022.12121746, PDF,  被引量   
作者: 王 莹, 迪 吉*：青海大学附属医院肿瘤内科，青海 西宁
关键词: NSCLC；VPI；诊断；临床病理特征；预后；NSCLC； VPI； Diagnosis； Clinicopathological Characteristics； Prognosis
摘要: 脏层胸膜侵犯(visceral pleural invasion, VPI)是非小细胞肺癌(non-small cell lung cancer, NSCLC)的预后不良因素。据报道PL0 (肿瘤位于胸膜下肺实质内或侵犯胸膜弹性层下的胸膜连接组织)肿瘤患者的5年总生存率，显著高于PL1 (肿瘤侵犯超过脏层胸膜弹性层)肿瘤患者及PL2 (肿瘤侵及脏层胸膜表面)肿瘤患者，(75.9%) VS (63.6%) (54.1%)。因此准确诊断及积极治疗VPI对改善NSCLC患者的预后有重要意义。目前临床上可以通过B超、CT检查等方法进行较好的预测，组织学诊断成为VPI诊断的金标准。年龄、性别、淋巴结转移、病理类型、EGFR (+)被认为与VPI的发生具有相关性，可以作为NSCLC患者发生VPI的风险因素。肺叶切除术加系统淋巴结清扫术是I期NSCLC患者的标准治疗方法，但I期NSCLC患者是否需要进行辅助化疗尚存有争议。本文就VPI诊断、临床病理特征及治疗的研究现状作一综述。
Abstract: Visceral pleural invasion (VPI) was found to be a poor prognostic factor for NSCLC. It was reported that the 5-year overall survival rate of patients with PL0 (tumor without pleural involvement be-yond its elastic layer) tumor (75.9%) was significantly higher than that of patients with PL1 (tumor that invades beyond the elastic layer) tumor (63.6%) and PL2 (tumor that invades to the pleural surface) tumor (54.1%). Therefore, accurate diagnosis and active treatment of VPI are of significance to improving the prognosis of patients with NSCLC. At present, B-ultrasound, CT ex-amination and other methods can be used in clinical prediction, histological diagnosis is the gold standard of VPI diagnosis. Age, gender, lymph node metastasis, pathological type and EGFR (+) are considered to be correlated with the occurrence of VPI and can be used as risk factors for the oc-currence of VPI in NSCLC patients. Lobectomy plus systematic lymph node dissection is the standard treatment for patients with stage I NSCLC, but the need for adjuvant chemotherapy is controversial. This article reviews the current status of diagnosis, clinicopathological features and treatment of VPI.
文章引用：王莹, 迪吉. 非小细胞肺癌发生胸膜侵犯的研究进展[J]. 临床医学进展, 2022, 12(12): 12115-12122. https://doi.org/10.12677/ACM.2022.12121746

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Travis, W.D., Brambilla, E., Nicholson, A.G., et al. (2015) The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of Thoracic Oncology, 10, 1243-1260. [Google Scholar] [CrossRef] 
[3] de Koning, H.J., van der Aalst, C.M., de Jong, P.A., et al. (2020) Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. The New England Journal of Medicine, 382, 503-513. [Google Scholar] [CrossRef] 
[4] Huang, H., Wang, T., Hu, B., et al. (2015) Visceral Pleural Invasion Remains a Size-Independent Prognostic Factor in Stage I Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery, 99, 1130-1139. [Google Scholar] [CrossRef] [PubMed]
[5] Liu, Q.X., Deng, X.F., Zhou, D., et al. (2016) Visceral Pleural Invasion Impacts the Prognosis of Non-Small Cell Lung Cancer: A Meta-Analysis. European Journal of Surgical Oncology, 42, 1707-1713. [Google Scholar] [CrossRef] [PubMed]
[6] 王鑫, 支修益. 国际肺癌研究协会(IASLC)第八版肺癌TNM分期解读[J]. 中华胸部外科电子杂志, 2016, 3(2): 70-76.
[7] Travis, W.D., Brambilla, E., Rami-Porta, R., et al. (2008) Visceral Pleural Invasion: Pathologic Criteria and Use of Elastic Stains: Proposal for the 7th Edition of the TNM Clas-sification for Lung Cancer. Journal of Thoracic Oncology, 3, 1384-1390. [Google Scholar] [CrossRef] 
[8] 吴怀申, 黄怡良. 肺癌侵犯胸壁和脏层胸膜的术前诊断[J]. 日本医学介绍, 1986(9): 407.
[9] 史赛敏, 许蟠熊. 周围型肺癌侵犯胸膜和胸壁的超声诊断[J]. 临床超声医学杂志, 2000(1): 43-44.
[10] Glazer, H.S., Duncan-Meyer, J., Aronberg, D.J., et al. (1985) Pleural and Chest Wall Invasion in Bronchogenic Carcinoma: CT Evaluation. Radiology, 157, 191-194. [Google Scholar] [CrossRef] [PubMed]
[11] Ebara, K., Takashima, S., Jiang, B., et al. (2015) Pleural Invasion by Peripheral Lung Cancer: Prediction with Three- Dimensional CT. Academic Radiology, 22, 310-319. [Google Scholar] [CrossRef] [PubMed]
[12] Onoda, H., Higashi, M., Murakami, T., et al. (2021) Correlation between Pleural Tags on CT and Visceral Pleural Invasion of Peripheral Lung Cancer That Does Not Appear Touching the Pleural Surface. European Radiology, 31, 9022-9029. [Google Scholar] [CrossRef] [PubMed]
[13] Hsu, J.S., Han, I.T., Tsai, T.H., et al. (2016) Pleural Tags on CT Scans to Predict Visceral Pleural Invasion of Non-Small Cell Lung Cancer That Does Not about the Pleura. Radiology, 279, 590-596. [Google Scholar] [CrossRef] [PubMed]
[14] 胸膜凹陷征形成的病理基础[J]. 中华结核和呼吸杂志, 1988, 11(3): 188.
[15] 冯耀. 非小细胞肺癌脏层胸膜侵犯预测方法的研究现状[J]. 中国癌症防治杂志, 2016, 8(2): 129-132.
[16] 范丽, 刘士远. 磁共振成像在肺癌诊断和鉴别诊断中的应用和研究现状[J]. 当代医学, 2009, 15(8): 124-131.
[17] Akata, S. (2008) Evaluation of Chest Wall Invasion by Lung Cancer Using Respiratory Dynamic MRI. Journal of Medical Imaging and Radiation Oncology, 52, 36-39. [Google Scholar] [CrossRef] [PubMed]
[18] 雷光, 曾亮, 陈雪, 等. 弹力纤维染色在恶性肿瘤中的研究进展[J]. 临床与实验病理学杂志, 2016, 32(9): 1037-1040.
[19] 周建云, 沈蓉, 代魁, 等. 弹性纤维染色在评估肺癌胸膜侵犯中的应用价值[J]. 中国组织化学与细胞化学杂志, 2020, 29(2): 171-174.
[20] 赵兰香, 余科科, 邵晋晨, 等. 弹力纤维染色在评估肺癌胸膜侵犯中的意义[J]. 临床与实验病理学杂志, 2014, 30(1): 22-24.
[21] Deng, H.Y., Li, G., Luo, J., et al. (2018) Novel Biologic Factors Correlated to Visceral Pleural Invasion in Early-Stage Non-Small Cell Lung Cancer Less than 3 cm. Journal of Thoracic Disease, 10, 2357-2364. [Google Scholar] [CrossRef] [PubMed]
[22] Zhang, H., Lu, C., Lu, Y., et al. (2016) The Predictive and Prog-nostic Values of Factors Associated with Visceral Pleural Involvement in Resected Lung Adenocarcinomas. OncoTargets and Therapy, 9, 2337-2348. [Google Scholar] [CrossRef] 
[23] Qi, L.P., Li, X.T., Yang, Y., et al. (2016) Multivariate Analysis of Pleural Invasion of Peripheral Non-Small Cell Lung Cancer-Based Computed Tomography Features. Journal of Com-puter Assisted Tomography, 40, 757-762. [Google Scholar] [CrossRef] 
[24] Kudo, Y., Saji, H., Shimada, Y., et al. (2012) Impact of Visceral Pleural Invasion on the Survival of Patients with Non-Small Cell Lung Cancer. Lung Cancer, 78, 153-160. [Google Scholar] [CrossRef] [PubMed]
[25] Shimizu, K., Yoshida, J., Nagai, K., et al. (2004) Visceral Pleural Invasion Classification in Non-Small Cell Lung Cancer: A Proposal on the Basis of Outcome Assessment. The Journal of Thoracic and Cardiovascular Surgery, 127, 1574-1578. [Google Scholar] [CrossRef] [PubMed]
[26] Imai, K., Minamiya, Y., Saito, H., et al. (2013) Detection of Pleural Lymph Flow Using Indocyanine Green Fluorescence Imaging in Non-Small Cell Lung Cancer Surgery: A Preliminary Study. Surgery Today, 43, 249-254. [Google Scholar] [CrossRef] [PubMed]
[27] Yu, Y., Huang, R., Wang, P., et al. (2020) Sublobectomy versus Lobectomy for Long-Term Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer with a Tumor Size Google Scholar] [CrossRef] [PubMed]
[28] Shi, J., Yang, Y., Zhao, Y., et al. (2019) EGFR Mutations Are Significantly Associated with Visceral Pleural Invasion Development in Non-Small-Cell Lung Cancer Patients. Cancer Management and Research, 11, 1945-1957. [Google Scholar] [CrossRef] 
[29] Le, H., Wang, X., Zha, Y., et al. (2017) Peripheral Lung Adenocar-cinomas Harboring Epithelial Growth Factor Receptor Mutations with microRNA-135b Overexpression Are More Likely to Invade Visceral Pleura. Oncology Letters, 14, 7931-7940. [Google Scholar] [CrossRef] [PubMed]
[30] Brewer III, L.A., Bai, A.F., Little, J.N. and Rabago y Pardo, G. (1958) Carcinoma of the Lung: Practical Classification for Early Diagnosis and Surgical Treatment. Journal of the American Medical Association, 166, 1149-1155. [Google Scholar] [CrossRef] [PubMed]
[31] Jiang, L., Liang, W., Shen, J., et al. (2015) The Impact of Visceral Pleural Invasion in Node-Negative Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Chest, 148, 903-911. [Google Scholar] [CrossRef] [PubMed]
[32] Luo, H., Qiao, L., Liang, N., et al. (2015) Risk Factors for Recurrence in Patients with Resected N1 Non-Small Cell Lung Cancer—A Systematic Review and Me-ta-Analysis. Journal of BUON, 20, 791-799.
[33] Hung, J.J., Jeng, W.J., Hsu, W.H., et al. (2012) Prognostic Signifi-cance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-Small Cell Lung Cancer. Chest, 142, 141-150. [Google Scholar] [CrossRef] [PubMed]
[34] Luo, H. (2015) Risk Factors for Recurrence in Patients with Resected N1 Non-Small Cell Lung Cancer—A Systematic Review and Meta-Analysis. Journal of BUON: Official Journal of the Balkan Union of Oncology, 20, 791-799.
[35] Scott, W.J., Howington, J., Feigenberg, S., et al. (2007) Treatment of Non-Small Cell Lung Cancer Stage I and Stage II: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest, 132, 234S-242S. [Google Scholar] [CrossRef] [PubMed]
[36] Mountain, C.F. (1998) Reflections on the Revisions in the International System for Staging Lung Cancer. Chest, 113, 1728-1729. [Google Scholar] [CrossRef] 
[37] 林一丹, 蒋耀光, 王如文, 等. 手术治疗96例I期NSCLC远期疗效分析[J]. 中国肺癌杂志, 2001, 4(6): 431-434.
[38] Ettinger, D.S., Wood, D.E., Aggarwal, C., et al. (2019) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. Journal of the National Comprehensive Cancer Network, 17, 1464-1472. [Google Scholar] [CrossRef] [PubMed]
[39] Ettinger, D.S., Wood, D.E., Aisner, D.L., et al. (2021) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network, 19, 254-266. [Google Scholar] [CrossRef] [PubMed]
[40] Donington, J., Ferguson, M., Mazzone, P., et al. (2012) American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation and Management for High-Risk Patients with Stage I Non-Small Cell Lung Cancer. Chest, 142, 1620-1635. [Google Scholar] [CrossRef] [PubMed]
[41] Strauss, G.M., Herndon, J.E., Maddaus, M.A., et al. (2008) Adjuvant Paclitaxel plus Carboplatin Compared with Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. Journal of Clinical Oncology, 26, 5043-5051. [Google Scholar] [CrossRef] 
[42] Pignon, J.P., Tribodet, H., Scagliotti, G.V., et al. (2008) Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Journal of Clinical Oncology, 26, 3552-3559. [Google Scholar] [CrossRef] 
[43] Arriagada, R., Bergman, B., Dunant, A., et al. (2004) Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 350, 351-360. [Google Scholar] [CrossRef] 
[44] Wu, Y.L., Tsuboi, M., He, J., et al. (2020) Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 383, 1711-1723. [Google Scholar] [CrossRef] 
[45] Winton, T., Livingston, R., Johnson, D., et al. (2005) Vinorelbine plus Cisplatin vs. Observation in Resected Non- Small-Cell Lung Cancer. The New England Journal of Medicine, 352, 2589-2597. [Google Scholar] [CrossRef] 
[46] Park, S.Y., Lee, J.G., Kim, J., et al. (2013) Efficacy of Plati-num-Based Adjuvant Chemotherapy in T2aN0 Stage IB Non-Small Cell Lung Cancer. Journal of Cardiothoracic Sur-gery, 8, 151. [Google Scholar] [CrossRef] [PubMed]

为你推荐